Francisella tularensis: Difference between revisions
No edit summary |
No edit summary |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
==Background== | ==Background== | ||
*Aerobic, gram-negative bacillus | *Aerobic, [[gram-negative]] bacillus | ||
==Clinical Features <ref> CDC. Tularemia. 2015 </ref> == | ==Clinical Features<ref> CDC. Tularemia. 2015 </ref>== | ||
*Ulceroglandular: MC form | *Ulceroglandular: MC form | ||
**Ulcer forms at the site of bacteria inoculation plus lymphadenopathy | **Ulcer forms at the site of bacteria inoculation plus lymphadenopathy | ||
Latest revision as of 01:14, 10 July 2017
Background
- Aerobic, gram-negative bacillus
Clinical Features[1]
- Ulceroglandular: MC form
- Ulcer forms at the site of bacteria inoculation plus lymphadenopathy
- Glandular
- Lymphadenopathy
- Oculoglandular
- Occurs when bacteria inoculates the eye
- Oropharyngeal
- Pharyngitis, tonsilitis
- Pneumonic
- Most serious
- Cough, dyspnea, chest pain
- Typhoidal
Antibiotic Sensitivities[2]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
Table Overview
| ||||||||||||||||||||||||||||||||||||||||